Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs)

Andreas Hochhaus, Carla Boquimpani, Delphine Rea, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna G. Turkina, Dong Wook Kim, Jane Apperley, Jorge E. Cortes, Andre Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp D. le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín García GutiérrezKoji Sasaki, Paola Aimone, Alex Allepuz, Sarah Quenet, Véronique Bédoucha, Michael J. Mauro

Research output: Contribution to journalArticlepeer-review

19 Scopus citations
Original languageEnglish (US)
StatePublished - Nov 19 2020

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this